Compare CNNE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | WVE |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 744.8M |
| IPO Year | 2017 | 2015 |
| Metric | CNNE | WVE |
|---|---|---|
| Price | $15.71 | $3.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $16.75 | ★ $18.06 |
| AVG Volume (30 Days) | 477.3K | ★ 2.9M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $499,700,000.00 | $3,704,000.00 |
| Revenue This Year | N/A | $19.21 |
| Revenue Next Year | $0.87 | N/A |
| P/E Ratio | $132.50 | ★ N/A |
| Revenue Growth | 3.37 | ★ 149.43 |
| 52 Week Low | $10.46 | $3.37 |
| 52 Week High | $19.00 | $21.73 |
| Indicator | CNNE | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 25.81 |
| Support Level | $15.08 | N/A |
| Resistance Level | $16.02 | $4.07 |
| Average True Range (ATR) | 0.36 | 0.21 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 59.62 | 9.86 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.